Monocyclic aromatic compounds are important for developing various drugs and treatments.
A new method creates valuable compounds for drug discovery by breaking traditional chemical rules.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
3 citations
,
May 2007 in “Journal of Heterocyclic Chemistry” A new method to make finasteride for hair loss treatment was developed.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
66 citations
,
January 1987 in “Journal of Investigative Dermatology” Coal tar shampoo increases enzyme activity in hair follicles, enhancing carcinogen binding to DNA.
October 2016 in “Letters in Drug Design & Discovery”
8 citations
,
March 2002 in “Archiv Der Pharmazie” The compound 4c effectively inhibits the enzyme linked to hair loss.
18 citations
,
January 2002 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
February 2023 in “European Journal of Medical Research” Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
The research created new azasteroids and pseudoazulenyl nitrones, which could be useful in medicine.
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
January 2023 in “IntechOpen eBooks” The document concludes that specific methods for making diazine-based drugs can lead to high yields and are important for creating effective treatments for various diseases.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
4 citations
,
January 1998 in “Heterocycles” Researchers made two new compounds that could be used for medicine.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
January 2026 in “RSC Medicinal Chemistry” 2,5-DBH shows promise for improving drugs in cancer, brain disorders, and infections.
January 2015 in “Journals & Books Hosting (International Knowledge Sharing Platform)” Compound 1 showed promising anticancer activity.
January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
January 2006 in “Benzina: Revista d'excepcions culturals” Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.